IP Library Granted Patent US 12,144,785
Granted Patent B2
US 12,144,785 · App. 15/151,970 · Granted Nov 19, 2024

Composition of vitamin K and vitamin D for treating or preventing cardiovascular disease

Inventor: Cees Vermeer (Maastricht, NL)
Assignee: NATTOPHARMA AS
A61K31/122A23L2/52A23L33/15A23L33/155A23L33/16A61K31/12A61K31/59A61K31/593A61K45/06A23V2002/00A61P9/00A61P9/04A61P9/10A61P9/12A61P9/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,144,785
App. No.
15/151,970
Granted
Nov 19, 2024
Kind
B2
Abstract

Vitamin K is effective in counteracting cardiovascular disorders such as the reduction in arterial elasticity normally associated with the aging process. A pharmaceutical composition or nutritional formulation comprising vitamin K can be used to combat age-related stiffening of the arteries, and the consequences thereof, namely pulmonary congestion, hypertension, left ventricular hypertrophy, congestive (right sided) heart failure, left sided or left ventricular failure, chronic cardiac failure, angina pectoris, myocardial infarction, Mönckeberg's sclerosis and stroke. In various embodiments, vitamin K can also be used to reduce or reverse calcification of a blood vessel in pre-existing cardiovascular disorders such as arteriosclerosis.

Claims (20)

1. A method of reversing calcification of a blood vessel in a human with existing artery disease, suffering from calcification of a blood vessel, and having diabetes and/or renal dysfunction, wherein said method of reversing calcification of a blood vessel includes removing pre-existing calcium deposits in the blood vessel, on the blood vessel, or a combination thereof,

wherein said method removes from about 10% to 100% of abnormal calcium deposits from the blood vessel and

said method comprises:

a) detecting pre-existing calcium deposits in the blood vessel, on the blood vessel, or a combination thereof in the human, and

b) administering vitamin K and vitamin D contained in a pharmaceutical or nutritional formulation to the human, wherein said vitamin K consists of vitamin K1, wherein said vitamin K1 and vitamin D are administered for a period of at least six months, and wherein said K1 is administered in an amount of from 100 μg to 200 μg/day and said vitamin D is administered in an amount of 5 μg to 20 μg/day.

2. The method according to claim 1 , wherein said calcification of a blood vessel is associated with calciphylaxis in end-stage renal disease.

3. The method according to claim 1 , wherein said calcification comprises calcification of the tunica media of the aorta or common carotid artery.

4. The method according to claim 1 , wherein the formulation further comprises at least one additional pharmaceutically active component.

5. The method according to claim 4 , wherein said at least one additional pharmaceutically active component is selected from the group consisting of anticoagulants, antithrombotics, fibrinolytics, antihypertensives, diuretics, antianginals, hypolipidaemic agents, beta-blockers, angiotensin-converting-enzyme (ACE) inhibitors, cardiac glycosides, phosphodiesterase inhibitors, antiarrhythmics, and calcium antagonists.

6. The method according to claim 1 , wherein the formulation further comprises at least one additional compound selected from the group consisting of polyphenols, vitamin C, vitamin E, L-Arginine, phytosterol, antihypertensive peptide, soluble fiber, omega-3 fatty acid(s), omega-6 fatty acid(s), omega-9 fatty acid(s), camitine, taurine, coenzyme Q10, creatine, folic acid, folates, magnesium, potassium, vitamin B6, and vitamin B12.

7. The method according to claim 1 , wherein the vitamin D is vitamin D3 (cholecalciferol).

8. The method according to claim 1 , wherein said human is a postmenopausal woman.

9. The method according to claim 1 , wherein said pre-existing calcium deposits are detected using a method selected from the group consisting of thallium stress testing, radiography, coronary calcification scans, fluoroscopy, CT, angioplasty, MRI, sonography, biopsy, and by histochemistry.

10. A method of restoring or improving vascular elasticity in a human suffering from vascular calcification, comprising:

a) detecting pre-existing calcium deposits in a blood vessel, on the blood vessel, or a combination thereof in the human, and

b) administering vitamin K and vitamin D contained in a pharmaceutical or nutritional formulation to the human, wherein said vitamin K consists of vitamin K1, wherein said vitamin K1 is administered in an amount between 100 μg to 200 μg per day and said vitamin D is administered in an amount of between 5 μg to 20 μg per day, wherein said vitamin K1 and vitamin D are administered for a period of at least six months, wherein restoring or improving vascular elasticity of a blood vessel includes removing the pre-existing calcium deposits in the blood vessel, on the blood vessel, or a combination thereof, and wherein said human pertains to a target population having diabetes and/or renal dysfunction.

11. The method of claim 10 , wherein said period is at least 36 months.

12. The method according to claim 10 , wherein the formulation further comprises at least one additional pharmaceutically active component.

13. A method of promoting healthy arteries in a human, comprising administering to the human an effective amount of vitamin K1 and vitamin D contained in a pharmaceutical or nutritional formulation, wherein the daily dosage of vitamin K1 is between 100 μg to 200 μg and vitamin D is between 5 μg to 20 μg, and said vitamin K1 and vitamin D are administered for a period of at least six months, and wherein said human pertains to a target population having diabetes and/or renal dysfunction.

14. The method according to claim 13 , wherein the formulation further comprises at least one additional pharmaceutically active component.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2023
From: VERMEER, CEES
To: VITAK BV
Reel/Frame 064723/0146 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2023
From: VERMEER, CEES
To: VITAK BV
Reel/Frame 064723/0248 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2023
From: VITAK BV
To: NATTOPHARMA ASA
Reel/Frame 064723/0325 →
CHANGE OF NAME Recorded Dec 20, 2022
From: PHARMACO AS
To: KAYDENCE PHARMA AS
Reel/Frame 062160/0444 →
MERGER Recorded Dec 20, 2022
From: KAYDENCE PHARMA AS
To: NATTOPHARMA AS
Reel/Frame 062160/0480 →
CHANGE OF NAME Recorded Dec 5, 2018
From: PHARMACO AS
To: KAYDENCE PHARMA AS
Reel/Frame 047722/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2018
From: NATTOPHARMA ASA
To: PHARMACO AS
Reel/Frame 044738/0241 →
Priority Claims (1)
GB 0220182 · Aug 30, 2002 · national
Continuity (3)
Division 11144853 · Jun 3, 2005
Continuation In Part 10525591
Related Publication 20160250160A1 · Sep 1, 2016